Stock DNA
Pharmaceuticals & Biotechnology
EUR 642 Million ()
NA (Loss Making)
NA
0.00%
-0.03
-67.89%
4.27
Revenue and Profits:
Net Sales:
48 Million
(Quarterly Results - Jun 2025)
Net Profit:
-12 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.95%
0%
-1.95%
6 Months
37.13%
0%
37.13%
1 Year
102.61%
0%
102.61%
2 Years
-22.29%
0%
-22.29%
3 Years
-44.53%
0%
-44.53%
4 Years
-83.68%
0%
-83.68%
5 Years
-45.86%
0%
-45.86%
Valneva SE for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.66%
EBIT Growth (5y)
-9.96%
EBIT to Interest (avg)
-5.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
13.38
Tax Ratio
2.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.11
EV to EBIT
-11.25
EV to EBITDA
-13.33
EV to Capital Employed
3.96
EV to Sales
3.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-35.21%
ROE (Latest)
-35.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
48.30
49.20
-1.83%
Operating Profit (PBDIT) excl Other Income
-7.90
-2.70
-192.59%
Interest
5.60
6.00
-6.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.60
-9.20
-26.09%
Operating Profit Margin (Excl OI)
-274.40%
-165.00%
-10.94%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -1.83% vs -6.99% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -26.09% vs 75.14% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
169.60
153.70
10.34%
Operating Profit (PBDIT) excl Other Income
-79.00
-86.50
8.67%
Interest
24.00
23.30
3.00%
Exceptional Items
10.90
11.40
-4.39%
Consolidate Net Profit
-12.20
-101.40
87.97%
Operating Profit Margin (Excl OI)
-581.20%
-677.10%
9.59%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 10.34% vs -57.46% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 87.97% vs 29.24% in Dec 2023
About Valneva SE 
Valneva SE
Pharmaceuticals & Biotechnology
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has also vaccines in development, including candidates against Clostridium difficile and Lyme Borreliosis. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products. It cooperates with various pharmaceutical companies using its technology platforms: EB66 vaccine production cell line and IC31 adjuvant. The Company has operations in France, Austria, Scotland, Canada and Sweden.
Company Coordinates 
Company Details
Campus Bio-Ouest, 6, Rue Alain Bombard , SAINT-HERBLAIN None : 44800
Registrar Details






